Related Experiment Video
Updated: Aug 31, 2025

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Use of sodium glucose co-transporter 2 inhibitors in acute heart failure: a practical guidance
João Pedro Ferreira1,2, Joana Pimenta3,4, Brenda Moura5
1UnIC@RISE, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal.
Aims:
Heart failure (HF) is the most frequent cause of hospital admission among patients 65 years or older. Patients hospitalized for acutely decompensated chronic HF and 'de novo' acute heart failure (AHF) continue to experience unacceptably high post-discharge readmission and mortality rates.
Methods And Results:
Until recently, trials had failed to improve outcome in patients with AHF irrespective of ejection fraction with exception of sodium-glucose co-transporter 2 inhibitors (SGLT2i) that improved clinical outcomes in patients hospitalized for AHF in the Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure (EMPULSE) and in the Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) trials.
Conclusions:
This document reviews the potential utility of SGLT2i in patients hospitalized for AHF.
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Heart Failure V: Medical Management
Secondary Active Transport
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: Diuretics
Acute Kidney Injury VI: Nursing Management

